<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883386</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00152719</org_study_id>
    <nct_id>NCT03883386</nct_id>
  </id_info>
  <brief_title>Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use</brief_title>
  <official_title>Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine
      targets histamine, and so may be effective in reducing bone pain.The researchers plan to
      prospectively assess the effectiveness of loratadine for chronic bone pain in patients with
      chronic G-CSF use.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain severity scores as measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
    <description>The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. The questions ask participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where &quot;0&quot; indicates &quot;No pain&quot; and &quot;10&quot; indicates &quot;Pain as bad as you can imagine.&quot;
Modified BPI: Included the pain intensity subscale, it is a Numerical Rating Scale with 4 questions (3-6): each item is ranked where 0 is no pain - 10 the worst pain.
The Modified BPI will be measured on Days 2, 4, and 6. The full BPI will be measured on Day 7. On day 7 only responses from questions 3-6 will be analyzed for this outcome and a mean composite score for Days 2, 4, 6, and 7 will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain interference in patients as measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
    <description>Brief Pain Inventory (BPI) asks the participant to rate how their pain interferes with daily activities where &quot;0&quot; indicates &quot;does not interfere and &quot;10&quot; indicates &quot;completely interferes&quot;. The Pain Intensity Scale scores (Numerical Rating Scale (NRS)) for 7 questions: general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life from (BPI question 9A-G); 0 no life interference - 10 complete interference. Pain interference will be assessed on day 7 of each week.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Bone Pain</condition>
  <arm_group>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take treatment daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take placebo daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>10 mg in a capsule</description>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered via capsule</description>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of neutropenia

          -  Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4
             times per month

          -  Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain
             Inventory (BPI)

        Exclusion Criteria:

          -  Other sources of chronic pain

          -  Previously tried loratadine for 7 consecutive days or more for bone pain

          -  Allergy to loratadine

          -  Chronic daily usage of antihistamine without an acceptable alternative
             non-antihistamine medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Walkovich</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kelly Walkovich</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics and Communicable Diseases</investigator_title>
  </responsible_party>
  <keyword>Granulocyte-colony stimulating factor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

